Secobarbital
| Secobarbital | |
|---|---|
| Salts [] | |
|---|---|
| Sodium secobarbital | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 238.28 g/mol [1] |
| Appearance | WHITE, AMORPHOUS OR CRYSTALLINE POWDER [1] |
| Odor | ODORLESS [1] |
| Taste | Slightly bitter [1] |
| Melting point | 100 °C [1] |
| Decomposition | When heated to decomposition it emits toxic fumes of /nitrogen oxides/. [1] |
| Solubility | 550 mg/L [1] |
| Predicted LogP | 2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C12H18N2O3 |
| IUPAC name | 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione |
| SMILES | CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C |
| InChI | InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17) |
| InChIKey | KQPKPCNLIDLUMF-UHFFFAOYSA-N |
| CAS number | 76-73-3 |
| UNII | 1P7H87IN75 |
| PubChem CID | 5193 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 15–40 hours[3] |
| Metabolism | Hepatic |
| Excretion | Renal |
| Routes of administration | By mouth, intravenous |
| Dependence liability | High |
| Addiction liability | High |
| Toxicity [] | |
|---|---|
| LD50 | Mouse: - oral: 267 mg/kg - ip: 116 mg/kg Rat: - oral: 125 mg/kg /Secobarbital - iv: 65 mg/kg /Seconal [1] |
Secobarbital (also known as Secobarbitone, Quinalbarbitone, Seconal, Quinalbarbital, Evronal, Hypotrol, Meballymal, Immenox, Secobarbitalum or Somosal) is a substance of the barbiturate class.
Chemistry
Salts []
Secobarbital is typically found in the form of its sodium salt.
Stereochemistry []
Secobarbital is a racemic mixture of the enantiomers (optical activity ( + / - )).
Druglikeness
Lipinski's rule of five
Secobarbital matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psycholeptics (N05)
- hypnotics and sedatives (N05C)
- barbiturates, plain (N05CA)
- secobarbital (N05CA06)
MeSH Classification
Mechanism of action []
Secobarbital binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| GABRA1 | shared target | 32 |
|---|---|---|
| GABRA2 | shared target | 32 |
| GABRA3 | shared target | 32 |
| GABRA4 | shared target | 32 |
| GABRA5 | shared target | 32 |
| GABRA6 | shared target | 32 |
| GABRB1 | shared target | 32 |
| GABRB2 | shared target | 32 |
| GABRB3 | shared target | 32 |
| GABRD | shared target | 32 |
| GABRE | shared target | 32 |
| GABRG1 | shared target | 32 |
| GABRG2 | shared target | 32 |
| GABRG3 | shared target | 32 |
| GABRP | shared target | 32 |
| GABRQ | shared target | 32 |
Medical side effects []
38 side effects listed on drug labels in SIDER 4.1 (secobarbital).
- Anaemia megaloblastic
- Angioedema
- Anxiety
- Apnoea
- Ataxia
- Confusional state
- Feeling abnormal
- Constipation
- Dermatitis exfoliative
- Dizziness
- Syncope
- Dermatitis
- Rash
- Body temperature increased
- Hallucination
- Headache
- Hypersensitivity
- Hypotension
- Nausea
- Nervousness
- Tension
- Nightmare
- Shock
- Loss of consciousness
- Vomiting
- Agitation
- Hyperkinesia
- Depressed level of consciousness
- Injection site reaction
- Hepatocellular injury
- Liver injury
- Thinking abnormal
- Mental disability
- Bradycardia
- Somnolence
- Hypoxia
- Respiratory failure
- Hypoventilation
Indications
- Insomnia
Legal status []
- Brazil: Secobarbital is a B1.[4]
- Canada: Secobarbital is a Schedule IV.
- Germany: Secobarbital is a Anlage III under the "Betäubungsmittelgesetz (BtMG)".
- United States: Secobarbital is a Schedule II except when combined in a dosage unit with another active drug (in which case Schedule III) under the "Controlled Substances Act".
- United Kingdom: Secobarbital is a Class B under the "Misuse of Drugs Act 1971".
- United Nations: Secobarbital is a Schedule II psychotropic under the "Convention on Psychotropic Substances 1971".
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5193, Secobarbital. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5193
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Secobarbital. UNII: 1P7H87IN75. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/1P7H87IN75
Secobarbital. http://www.merck.com/mmpe/lexicomp/secobarbital.html
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 16:33:40 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 16:33:36 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 16:33:35 |
| gsrs | ok | 2026-11-20 16:33:37 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014562) | 2026-11-20 16:33:35 |
| kegg | ok | 2026-11-20 16:33:38 |
| pubchem | ok | 2026-11-20 16:33:34 |
| missing (no r/tripreports posts mention it) | 2026-11-20 16:33:35 | |
| sider | ok | 2026-11-20 16:33:36 |
| structure | ok | 2026-11-20 16:33:35 |
| wikipedia | ok | 2026-11-20 16:33:36 |